Activation of transient receptor potential vanilloid 4 increases NMDA-activated current in hippocampal pyramidal neurons

Lin Li<sup>1,2</sup>, Weijun Qu<sup>1</sup>, Libin Zhou<sup>1</sup>, Zihong Lu<sup>1</sup>, Pinghui Jie<sup>1</sup>, Lei Chen<sup>1</sup>* and Ling Chen<sup>1,2</sup>*

<sup>1</sup> Department of Physiology, Nanjing Medical University, Nanjing, China
<sup>2</sup> State Key Laboratory of Reproductive Medicine, Nanjing Medical University, Nanjing, China

INTRODUCTION

Stroke is a worldwide health problem leading to high rates of death and neurological disability in adults. The mechanisms underlying cerebral ischemia injury are complex, but the intracellular free calcium ([Ca<sup>2+</sup>]<sub>i</sub>) overload has been proved to play a vital role (Szydlowska and Tymianski, 2010). It is generally accepted that during cerebral ischemia, a large amount of glutamate accumulates in the synaptic cleft, which results in excessive calcium influx through N-methyl-D-aspartate receptors (NMDARs), to trigger and eventually induce cell death (Paschen, 1996). The glutamate excitotoxicity has long been recognized, however, treatment by directly targeting glutamate receptors has failed in clinical trials either because of intolerable side effects or lack of medical efficacy (Kemp and McKernan, 2002).

Apart from neuronal death, another critically important pathophysiological process in ischemic stroke is the formation of brain edema which includes the cytotoxic and vasogenic edema (Simard and Gibson, 2009). During ischemia, the energy failure results in cytotoxic edema and membrane lipid metabolism disorder causing extra release of free AA (Westerberg et al., 1987; Marmarou, 2007; Simard et al., 2007). Therefore, it is very likely that TRPV4 during cerebral ischemia, but also contributes to the adverse outcome (Marmarou, 2007; Simard et al., 2007). Therefore, prevention of brain edema or alleviation of brain edema-induced injury is critical for the treatment of cerebral ischemia.

Recently, there is accumulating evidence concerning the involvement of Transient Receptor Potential (TRP) channels, a potentially important calcium influx pathway, in cerebral ischemia injury. For example, TRP melastatin (TRPM) members, especially TRPM2 and TRPM7, are important contributors to the neuronal death following ischemia (Sun et al., 2009; Bai and Lipski, 2010). Besides TRPM channels, other TRP family members might also be responsible for ischemic neuronal injury. Among them, TRV vanilloid 4 (TRPV4) is attracting more and more attention because it can be activated by multiple stimuli including hypotonic stimulation, cell swelling, mild heat (>24-37°C), arachidonic acid (AA), and its metabolism epoxyeicosatrienoic acids (EETs; Plant and Strotmann, 2007), some of which may happen during stroke. TRPV4 is widely expressed in the central nervous system, including hippocampus, cortex, thalamus, and cerebellum etc. (Kauer and Strotmann, 2007). TRPV4 plays an important role in cerebral ischemia injury. Transient receptor potential vanilloid 4 (TRPV4) can be activated by multiple stimuli that may happen during stroke. The present study evaluated the effect of TRPV4 activation on NMDA-activated current (I<sub>NMDA</sub>) and that of blocking TRPV4 on brain injury after focal cerebral ischemia in mice. We herein report that activation of TRPV4 by 4α-PDD and hypotonic stimulation increased I<sub>NMDA</sub> in hippocampal CA1 pyramidal neurons, which was sensitive to TRPV4 antagonist HC-067047 and NMDAR antagonist AP-5, indicating that TRPV4 activation potentiates NMDAR response. In addition, the increase in I<sub>NMDA</sub> by hypotonicity was sensitive to the antagonist of NMDAR NR2B subunit, but not of NR2A subunit. Furthermore, antagonists of calcium/calcmodulin-dependent protein kinase II (CaMKII) significantly attenuated hypotonicity-induced increase in I<sub>NMDA</sub>, while antagonists of protein kinase C or casein kinase II had no such effect, indicating that phosphorylation of NR2B subunit by CaMKII is responsible for TRPV4-potentiated NMDAR response. Finally, we found that intracerebroventricular injection of HC-067047 after 60 min middle cerebral artery occlusion reduced the cerebral infarction with at least a 12 h efficacious time-window. These findings indicate that activation of TRPV4 increases NMDAR function, which may facilitate glutamate excitotoxicity. Closing TRPV4 may exert potent neuroprotection against cerebral ischemia injury through many mechanisms at least including the prevention of NMDAR-mediated glutamate excitotoxicity.

Keywords: TRPV4, NMDA receptor, NR2B subunit, phosphorylation, excitotoxicity, cerebral ischemia
is hyper-activated during ischemia, leading to an increase in calcium influx. Blockage of TRPV4 by lowering temperature may be responsible for the neuroprotection against oxygen-glucose deprivation-induced injury (Lipski et al., 2006). TRPV4 blockers GdCl₃ and ruthenium red increase the viability of astrocytes exposed to oxidative stress (Bai and Lipski, 2010). But for the lack of selectivity of these blockers, the role of TRPV4 in cerebral ischemia injury remains to be determined. HC-067047 is recently described as a potent and specific TRPV4 antagonist. It is reported that HC-067047 can inhibit mouse TRPV4 activation by various stimuli, including heat, hypotonic stimulation, AA, 4° cold, and reperfusion (Everaerts et al., 2010). The selectivity of HC-067047 makes it more promising and possible to explore the involvement of TRPV4 in cerebral ischemia.

Hippocampus is highly susceptible to ischemia among brain regions and pyramidal neurons of CA1 region are most sensitive to ischemia damage (Schmidt-Kastner and Freund, 1991). Concerning that the entry of Ca²⁺ through NMDAR is the major pathway leading to excitotoxic cell death associated with ischemia, the present study firstly tested the effect of TRPV4 activation on NMDA-activated current (I₅₋ₓ₈) in hippocampal CA1 pyramidal neurons and then explored the mechanisms underlying TRPV4-action. We also tested the effect of HC-067047 on brain infarction in focal cerebral ischemia model mice.

MATERIALS AND METHODS

ANIMALS

Male mice (ICR, Oriental Bio Service Inc., Nanjing) were used in the study. Care of animals conformed to standards established by the National Institutes of Health. All animal protocols were approved by the Nanjing Medical University Animal Care and Use Committee (ID: 20110628). All efforts were made to minimize animal suffering and to reduce the number of animals used.

SLICE PREPARATION

Mice (3-week-old) were decapitated under deep anesthesia with ethyl ether. The brains were rapidly removed and the coronal brain slices (400 µm) were cut using a vibrating microtome (Microslicer DTK 1500, Dousaka EM Co, Kyoto, Japan) in ice-cold modified artificial cerebrospinal fluid (mACSF) composed of (in mM) NaCl 126, CaCl₂ 2.5, KCl 2.5, NaHCO₃ 26, KH₂PO₄ 1.25, n-glucose 20, and n-mannitol 80 at osmolality of 300 mOsm/kg. When recording I₅₋ₓ₈, hippocampal pyramidal neurons were held at −60 mV. NMDA together with glycine (10 µM) were dissolved in bath solution and focally applied using a rapid drug delivery system directed toward the soma of recorded neurons. One micrometer strychnine, 10 µM bicuculline, 10 µM NBQX, and 0.1 µM tetrodotoxin (TTX) were added in bath solution to block glycine receptor, GABA receptor, AMPA receptor, and voltage-gated sodium channels, respectively. When recording 4°-PDD-evoked current, 10 µM 4°-PDD and 0.1 µM TTX were added in mACSF and a ramp protocol depolarizing from −80 to +80 mV over 700 ms was used. Hypotonic solution was obtained by adjusting the concentration of n-Mannitol. The osmolality was measured using the Advanced Micro Osmometer, model 3300 (Advanced instruments Inc., Norwood, MA, USA).

DRUG TREATMENT

For intracerebroventricular (icv) implantation, mice (weighing 25–30 g) were anesthetized with chloral hydrate. A guide cannula (2.5 mm length, 23 gage) was implanted in the left lateral ventricle. HC-067047 stock solution was freshly diluted with 0.9% sodium chloride on the day of experiment. HC-067047 (10 µmol/2 µl/mouse) was injected with a stepper-motorized microsyringe (Stoelting, Wood Dale, IL, USA) at a rate of 0.5 µl/min. Control mice were given an equal volume of vehicle. HC-067047 was firstly injected 4 h (HC-4 h), 8 h (HC-8 h), and 12 h (HC-12 h) after middle cerebral artery occlusion (MCAO), respectively, and then injected every 8 h.

PREPARATION OF FOCAL CEREBRAL ISCHEMIA MODEL

Three days after cannula implantation, focal cerebral ischemia was induced by MCAO as previously described (Mulcahy et al., 2003). Briefly, after mice were anesthetized, a poly-L-lysine (0.1%, weight/volume)-coated nylon monofilament thread (3/0 gage with the tip heat blunted to a diameter of 0.104 mm) was inserted through the external carotid artery and advanced into the internal carotid artery to occlude the origin of the middle cerebral artery (approximately 12 mm). Adequacy of vascular occlusion and reperfusion was monitored in the front parietal cortex of the occluded side with a multichannel laser Doppler flow-meter (Perimed PF5050, Sweden). Body and head temperatures were controlled at 37 ± 0.5°C with a thermostatically controlled heating pad. Arterial blood pressure and gases were monitored through a femoral catheter. After MCAO for 60 min, the filament was withdrawn for reperfusion. Sham-operated (sham-op) animals were treated identically, except that the MCAs were not occluded after neck incision.

INFARCTION VOLUME MEASUREMENT

Brains were removed at 24 h post-MCAO, sectioned into five equidistant coronal slices (2-mm-thick), and incubated with a 2%
As glutamate excitotoxicity is of great importance in cerebral life Science (Ann Arbor, MI, USA). Others, unless stated, all came from Sigma Chemical Company.

CHEMICALS
4α-phorbol-12,13-didecanoate (4α-PDD) was obtained from Calbiochem (San Diego, CA, USA) and TTX was obtained from Enzo Life Science (Ann Arbor, MI, USA). Others, unless stated, all came from Sigma Chemical Company.

4α-PDD, HC-067047, α-Sphingosine, bisindolylmaleimide II (BIM), TBB, DRB and KN62, NBQX, and strychnine were prepared as stock solutions in DMSO. The final concentration of DMSO in the bath chamber or pipette solution was <0.1%. KN93, KN62, and α-Sphingosine were present in the pipette solution, while d(-)-2-Amino-5-phosphonopentanoic acid (AP-5), ifenprodil, PEAAQ tetrasodium hydrate (NVP-AAM007), 4α-PDD, HC-067047, BIM, phorbol-12-myristate 13-acetate (PMA), TBB, DRB, NBQX, strychnine, bicusculine, and strychnine were added to bath solution.

DATA ANALYSIS
Data are expressed as means ± standard error and were analyzed with PulseFit (HEKA Elektronik) and Stata 7.0 software (STATA Corporation, USA). In the present study, after testing the effect of 4α-PDD and hypotonicity on INMDA, 10 µM 4α-PDD was applied to the same neuron to test whether the neuron had TRPV4 receptors. All data came from the neurons where 4α-PDD-evoked current could be recorded. Before data analysis, both normality of the distribution and homogeneity of variance were assessed by Shapiro-Wilk test of the distribution and homogeneity of variance were assessed by ANOVA followed by Bonferroni’s post hoc test were used for post hoc analysis with the significance level set at P < 0.05 in each case; Figure 2A). Hypotonic stimulation increased INMDA by 39.0% from -25.01 ± 2.71 to -34.13 ± 2.82 pA/pF (n = 17, paired t-test, P < 0.05). The increase in INMDA by hypotonic stimulation was more evident with larger osmotic gradient (Figure 2E), and the following experiments were performed using hypotonic stimulation of 240 mOsm/kg which produced the significant increase in INMDA.

HYPOTONIC STIMULATION INCREASES INMDA IN HIPPOCAMPAL CA1 PYRAMIDAL NEURONS
As a cellular osmotic sensor, TRPV4 is sensitive to hypotonic stimuli. Here, we tested the effect of hypotonic stimulation on INMDA. When the external solution was changed from isotonicity (300 mOsm/kg) to hypotonicity (240 mOsm/kg), INMDA was increased by 39.0 ± 5.4% from -25.01 ± 2.71 to -34.13 ± 2.82 pA/pF (n = 17, paired t-test, P < 0.05; Figure 2A). The increase in INMDA by hypotonic stimulation was more evident with larger osmotic gradient (Figure 2E), and the following experiments were performed using hypotonic stimulation of 240 mOsm/kg which produced the significant increase in INMDA.

RESULTS
4α-PDD INCREASES INMDA IN HIPPOCAMPAL CA1 PYRAMIDAL NEURONS
As glutamate excitotoxicity is of great importance in cerebral ischemia injury, we firstly explored whether TRPV4 activation modulated NMDAR function. After application of 30 µM NMDA (for 20 s) and its co-agonist glycine onto hippocampal CA1 pyramidal neuron an inward current was recorded. This INMDA was blocked by the specific NMDAR antagonist AP-5 (50 µM), suggesting its mediation by NMDAR (Figure 1B). Here, it was found that INMDA was markedly increased by 31.6 ± 2.1% from -24.67 ± 1.04 to -32.33 ± 2.78 pA/pF after application of TRPV4 agonist 4α-PDD (10 µM) for 5 min (n = 10, paired t-test, P < 0.01). The increase in INMDA was reversible after 4α-PDD was washed out (Figure 1A). It was noted that in the presence of AP-5, 4α-PDD almost had no effect on the current (n = 6, paired t-test, P > 0.05; Figure 1B).

We then studied the effect of 4α-PDD on dose-response curve of INMDA. EC50 and n values of dose-response curve were 19.91 ± 1.74 µM and 1.74 in the absence of 4α-PDD, respectively. After application of 4α-PDD, the maximal response to 300 µM NMDA was markedly increased (n = 6, paired t-test, P < 0.01), but EC50 (19.93 ± 1.67 µM) and n values (1.63) were almost unaffected (unpaired t-test, P > 0.05 in each case; Figure 1C).

We also performed experiments on current-voltage relationship of INMDA. Application of 4α-PDD markedly increased INMDA at different voltages ranging from -80 to +60 mV. For example, when the holding potential was -80 mV, INMDA was significantly increased from -27.90 to -35.95 pA/pF (n = 8, paired t-test, P < 0.01). In I-V curve of INMDA, the reversal potential was 9.61 ± 1.83 mV, which was not significantly different from the control (9.29 ± 1.58 mV; n = 8, paired t-test, P > 0.05). Besides this, we also compared the ratio of current at +60/-80 mV to find that the ratio was not affected by 4α-PDD (control: -0.28; 4α-PDD: -0.29, n = 8, paired t-test, P > 0.05; Figure 1D).

THE SPECIFIC TRPV4 ANTAGONIST HC-067047 ATTENUATES 4α-PDD AND HYPOTONICITY-INDUCED INCREASE IN INMDA
HC-067047 is a recently discovered specific TRPV4 antagonist (Everaerts et al., 2010). The present study showed that pre-application of HC-067047 (1 µM) markedly attenuated the increase in INMDA by both hypotonicity and 4α-PDD (unpaired
PATHWAYS IS INVOLVED IN HYPOTONICITY-INCREASED CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE II SIGNALING

µ units are prominent in the hippocampus (Laurie et al., 1997). binds to glutamate. In the adult brain, both NR2A and NR2B subunits contain the glycine binding site, and an NR2 (A-D) subunit, which Functional NMDAR is composed of both an NR1 subunit, which contains the CaMKII, protein kinase C (PKC), and casein kinase II (CKII) pathways that can modulate the function of NMDAR (Chen and Roche, 2007). The following experiments were performed in isotonic and hypotonic solution to explore the possible mechanisms underlying TRPV4-mediated increase in INMDA.

NR2B SUBUNIT IS INVOLVED IN HYPOTONICITY-INCREASED INMDA

Functional NMDAR is composed of both an NR1 subunit, which contains the glycine binding site, and an NR2 (A-D) subunit, which binds to glutamate. In the adult brain, both NR2A and NR2B subunits are prominent in the hippocampus (Laurie et al., 1997). In the presence of ifenprodil (10 μM), a specific NR2B subunit inhibitor, hypotonicity-induced increase in INMDA was markedly attenuated (n = 33, unpaired t-test, P < 0.01; Figure 4A). By contrast, pre-application of NVP-AAM007 (0.3 μM), a specific inhibitor of NR2A subunit, the increase in INMDA by hypotonicity was unaffected (n = 29, unpaired t-test, P > 0.05; Figure 4B).

CALCULUM/CALMODULIN-DEPENDENT PROTEIN KINASE II SIGNALING PATHWAYS IS INVOLVED IN HYPOTONICITY-INCREASED INMDA

The NMDAR subunits possess phosphorylation sites for protein kinases that can modulate the function of NMDAR (Chen and Roche, 2007). The following experiments were performed to test whether Calcium/calmodulin-dependent protein kinase II (CaMKII), protein kinase C (PKC), and casein kinase II (CKII) pathways were responsible for hypotonicity-increased INMDA. As CaMKII plays an important role in phosphorylation of NMDAR, here we firstly evaluated the effect of CaMKII antagonists KN62 and KN93 on INMDA in isotonic solution. Pre-incubation of KN62 (5 μM) or KN93 (3 μM) decreased INMDA from -25.50 ± 1.15 to -21.01 ± 2.71 pA/pF (n = 7, paired t-test, P < 0.05) and from -25.08 ± 2.14 to -20.06 ± 1.56 pA/pF (n = 8, paired t-test, P < 0.05), respectively. As shown in Figure 5A, with KN62 or KN93 in the pipette solution, INMDA was increased 8.5 ± 3.8% (n = 15) and 8.7 ± 3.6% (n = 17) by hypotonicity, respectively, both of which were significantly different from hypotonicity-increased INMDA without antagonism of CaMKII (unpaired t-test, P < 0.01 in each case). This result suggests that CaMKII is responsible for the increase in INMDA caused by TRPV4 activation.

In isotonic solution, INMDA was increased from -24.42 ± 2.78 to -27.51 ± 0.84 pA/pF by PMA (agonist of PKC, 1 μM; n = 6, paired t-test, P < 0.05). After pre-application of PKC antagonists d-Sphingosine (20 μM) or BIM (1 μM), INMDA was decreased from -24.69 ± 0.94 to -21.63 ± 1.33 pA/pF (n = 9, paired t-test, P < 0.05) and from -25.04 ± 2.01 to -20.06 ± 1.56 pA/pF (n = 7, paired t-test, P < 0.05), respectively. Figure 5B shows that pre-incubation of d-Sphingosine or BIM did not affect the increase in INMDA by hypotonicity (unpaired t-test, P > 0.05 in each case). We also tested the role of CKII signaling pathway, for this pathway is reported to specially phosphorylate NR2B subunit. Here, it was found that application of CKII antagonist TBB (10 μM) or DRB
FIGURE 2 | Hypotonic stimulation increases $I_{\text{NMDA}}$ in hippocampal CA1 pyramidal neurons. (A) The typical recordings show that $I_{\text{NMDA}}$ was increased from $-1.73$ to $-2.42$ nA when the extracellular isotonic solution (300 mOsm/kg) was changed to hypotonic solution (240 mOsm/kg) and the current recovered to $-1.81$ nA after washout. 4α-PDD-evoked current was recorded in the same neuron. (B) $I_{\text{NMDA}}$ was reduced from $-25.74 \pm 3.12$ to $-2.67 \pm 0.87$ pA/pF by AP-5 ($n = 6$, paired t-test, $P < 0.01$). Note that in the presence of AP-5, the current was not changed by hypotonic stimulation. **$P < 0.01$ vs. 300 mOsm/kg. (C) Dose-response curves for $I_{\text{NMDA}}$ in isotonic and hypotonic solution. Each point represents the normalized current from 7 to 17 hippocampal neurons. EC$_{50}$ values were $19.23 \pm 1.89$ and $18.24 \pm 1.07$ µM, and $n$ were 1.71 and 1.79 for isotonicity and hypotonicity, respectively. (D) I-V curves were shown in isotonic and hypotonic solution. (E) The plot shows that hypotonic stimuli exhibited more increase in $I_{\text{NMDA}}$ with larger osmotic gradient.

FIGURE 3 | TRPV4 antagonist blocks 4α-PDD- and hypotonicity-increased $I_{\text{NMDA}}$. (A) In the presence of HC-067047, $I_{\text{NMDA}}$ was almost not changed by hypotonic stimulation and the increase in $I_{\text{NMDA}}$ by hypotonicity was decreased from $39.0 \pm 5.4\%$ ($n = 17$) to $4.1 \pm 2.2\%$ ($n = 21$). **$P < 0.01$ vs. 240 mOsm/kg. (B) Pre-application of HC-067047, the increase in $I_{\text{NMDA}}$ by 4α-PDD was decreased from $31.6 \pm 2.1\%$ ($n = 10$) to $3.3 \pm 3.1\%$ ($n = 18$). ##$P < 0.01$ vs. 4α-PDD.

(100 µM) decreased $I_{\text{NMDA}}$ from $-25.01 \pm 5.95$ to $-18.19 \pm 2.50$ pA/pF ($n = 7$, paired t-test, $P < 0.01$), and from $-24.94 \pm 1.49$ to $-17.16 \pm 1.57$ pA/pF ($n = 7$, paired t-test, $P < 0.01$), respectively. Figure 5C shows that in the presence of TBB or DRB, $I_{\text{NMDA}}$ was increased $41.1 \pm 4.0\%$ ($n = 24$) and $40.2 \pm 4.7\%$ ($n = 10$) by hypotonicity, respectively, both of which were similar to the increase in $I_{\text{NMDA}}$ by hypotonicity alone (unpaired t-test, $P > 0.05$ in each case). These results indicate that neither PKC nor...
Li et al. TRPV4-mediated increase in NMDA-current

FIGURE 4 | NR2B subunit antagonist attenuates hypotonicity-increased $I_{\text{NMDA}}$. (A) In the presence of ifenprodil, the current was almost not changed by hypotonic stimulation and the increase in $I_{\text{NMDA}}$ by hypotonicity was markedly attenuated from 39.0 ± 5.4% ($n = 17$) to 3.8 ± 1.8% ($n = 18$). ** $P < 0.01$ vs.

CKII signaling system is involved in TRPV4 activation-induced increased $I_{\text{NMDA}}$.

TRPV4 ANTAGONIST REDUCES BRAIN DAMAGE AFTER FOCAL CEREBRAL ISCHEMIA

The neuroprotection of blocking TRPV4 was tested in vivo using MCAO mice to induce focal cerebral ischemia. Figure 6A shows a representative experiment that the area of non-viable tissue, as indicated by pale color, was much smaller (3.0 ± 1.8%, $n = 10$) in the infracted hemisphere when mice were treated with HC-067047 (HC-4 h), compared with the mice treated with vehicle (35.3 ± 4.2%, $n = 10$; ANOVA followed by Bonferroni’s post hoc test, $P < 0.01$). Furthermore, HC-067047, when was firstly administered 8 h (HC-8 h, 17.1 ± 5.8%, $n = 10$) or 12 h (HC-12 h, 18.2 ± 4.1%, $n = 10$) post-MCAO, could markedly reduce the size of infarction (ANOVA followed by Bonferroni’s post hoc test, $P < 0.05$ in each case; Figure 6B). These results suggest that blockage of TRPV4 reduces MCAO-induced cerebral injury with an efficacious time-window of at least 12 h.

DISCUSSION

Cytotoxic edema is an important pathological process as well as a major cause of neuronal death in cerebral ischemia injury (Marmarou, 2007; Simard et al., 2007). Activation of TRPV4 is likely for its sensitivity to cell swelling, AA, and its metabolism EETs, which are always associated with cerebral ischemia. During ischemia, glutamate-induced intracellular calcium overload, which is mediated through NMDAR, plays an important role in neuronal injury. In this study, we found that application of 4α-PDD or hypotonic stimulation enhanced $I_{\text{NMDA}}$ in hippocampal CA1 pyramidal neurons, which was markedly attenuated by the specific TRPV4 antagonist HC-067047 (Figure 3), indicating that activation of TRPV4 leads to the increase in $I_{\text{NMDA}}$. Additionally, 4α-PDD- or hypotonicity-increased $I_{\text{NMDA}}$ was blocked by NMDAR antagonist AP-5, indicating that TRPV4 potentiates NMDAR response (Figures 1B and 2B). It is known that NMDARs are calcium-permeable and the opening of these channels leads to further membrane depolarization and greater calcium influx, exacerbating intracellular calcium overload. Therefore, TRPV4-induced enhancement of NMDAR response may helps to facilitate glutamate-neurotoxicity during stroke.

The increase in $I_{\text{NMDA}}$ probably results from an increase in NMDAR expression or enhanced NMDAR function. The present study mainly focused on the latter, for there is a report that NMDAR subunits expression is unaffected in TRPV4 knockout mice (Shibasaki et al., 2007). Although the maximal $I_{\text{NMDA}}$ was increased, $EC_{50}$ value in dose-response curve was not changed by either 4α-PDD or hypotonicity (Figures 1C and 2C), indicating that TRPV4-action is not dependent on increasing ligand binding affinity. Additionally, 4α-PDD and hypotonicity did not change the reversal voltage or $I(+60\text{mV})/I(-80\text{mV})$ ration in $I-V$ curve (Figures 1D and 2D), indicating that TRPV4-action is voltage-independent. It has been demonstrated that NR2B subunit is critical for a number of basic structural and functional attributes associated with NMDAR (Loftis and Janowsky, 2003). In this study, selective antagonism of NR2B but not NR2A subunit markedly blocked hypotonicity-induced increase in $I_{\text{NMDA}}$ (Figure 4), suggesting the involvement of NR2B subunit in TRPV4-induced $I_{\text{NMDA}}$. Increasing evidence supports the notion that the level of
Li et al. TRPV4-mediated increase in NMDA-current

FIGURE 5 | CaMKII antagonists attenuate hypotonicity-increased $I_{\text{NMDA}}$. (A) In the presence of KN62 or KN93, $I_{\text{NMDA}}$ was almost not affected by hypotonic stimulation and the increase in $I_{\text{NMDA}}$ by hypotonicity was markedly blocked by pre-application of KN62 or KN93. **$P < 0.01$ vs. 240 mOsm/kg. (B) $I_{\text{NMDA}}$ was increased 36.2 ± 4.0% ($n = 20$) and 33.7 ± 4.9% ($n = 12$) by hypotonic stimulation in the presence of d-sphingosine or BIM, respectively. (C) Pre-incubation of TBB or DRB did not affect the increase in $I_{\text{NMDA}}$ by hypotonicity.

FIGURE 6 | TRPV4 antagonist reduces brain damage after focal cerebral ischemia. (A) Representative photographs of cerebral infarction in MCAO mice treated with HC-067047. Note that treatment with HC-067047 (HC-4 h) after stroke significantly reduced the MCAO-induced cerebral infarction. (B) Time-window of neuroprotective effect of HC-067047. Bar graphs show the mean infarct volume percentage in MCAO mice that were treated with HC-067047 starting 4, 8, and 12 h post-MCAO. **$P < 0.01$ and *$P < 0.05$ vs. vehicle-treated MCAO mice, #P < 0.05 vs. HC-4 h.
NR2B subunit phosphorylation is linked to the receptor activity, leading to the prolonged calcium influx. Our previous studies have reported that some intracellular signaling pathways are responsible for hypotonicity (TRPV4)-induced modulation on voltage-gated ion channels and TRPV1 receptor (Liu et al., 2007; Chen et al., 2008a,b, 2009; Li et al., 2011b). Here, CaMKII, PKC, and CKII signaling pathways were selected for they are responsible for phosphorylation of NR2B subunit (Chen and Roche, 2007). We found that the increase in \( I_{\text{NMDA}} \) by hypotonic stimulation was markedly attenuated by CaMKII, but not PKC or CKII antagonists (Figure 5). These results indicate that the phosphorylation of NR2B subunit by CaMKII is responsible for TRPV4-induced increase in \( I_{\text{NMDA}} \). It is known that activation of CaMKII is necessary before it phosphorylates NMDAR, which is dependence on \( \text{Ca}^{2+}/\text{CaM} \). TRPV4 activation increased \( I_{\text{NMDA}} \), which may facilitate calcium influx through NMDAR and exacerbate the increase of \( [\text{Ca}^{2+}]_i \), \( \text{Mg}^{2+} \), which mainly exists inside of cell in normal condition, is very important for the activation of some kinases. The present recording solution was lack of \( \text{Mg}^{2+} \), suggesting that this recording condition may not be optimal condition for CaMKII activity. However, activation of CaMKII was still possible, which was caused by \( \text{Mg}^{2+} \) inside of neurons. Here, pre-application of CaMKII antagonists KN62 and KN93 inhibited \( I_{\text{NMDA}} \) in isotonic solution, which was consistent with the above deduction. It is reported that \( \text{Ca}^{2+}/\text{calmodulin-activated Ser-Thr kinase (CASK)} \), which functions as an active protein kinase even without \( \text{Mg}^{2+} \) binding, may associated with CaMKII and modulate its phosphorylation state (Mukherjee et al., 2008). Whether CASK is involved CaMKII-induced modulation of NMDAR function remains unclear in the present study. On the other hand, the C terminus of TRPV4 contains a PDZ-binding-like motif that may contribute to the interaction of TRPV4 with PDZ-domain proteins (Garcia-Elias et al., 2008). Therefore, there may be other possibility that TRPV4 per se influences the activation of CaMKII.

Another important result of this study is that we firstly provide in vivo evidence that closing TRPV4 exerts potent neuroprotection against cerebral ischemic injury with at least a 12 h efficacious time-window (Figure 6). In fact, over-activation of TRPV4 may induce neuronal injury in cerebral ischemia through multiple mechanisms. In cultured hippocampal pyramidal neurons, application of glutamate induces more \( \text{[Ca}^{2+}]_i \), increase at 37°C than at 25°C, which is more evident in wild type neurons than in TRPV4 knockout neurons. Moreover, this temperature-dependent \( \text{[Ca}^{2+}]_i \), increase at 37°C was markedly inhibited by a NMDAR blocker in wild type but not in TRPV4 knockout neurons, which indicates that TRPV4 activation promotes NMDAR activation in hippocampal pyramidal neurons (Shibasaki et al., 2007). Consistently, the present study showed that activation of TRPV4 enhanced \( I_{\text{NMDA}} \) in hippocampal CA1 pyramidal neurons. On the other hand, activation of TRPV4 can depolarize the resting membrane potential (Shibasaki et al., 2007), which helps the release of presynaptic glutamate. Our experiment performed on the excitatory postsynaptic current (EPSC) also showed that TRPV4 agonist 4e-PDD increased EPSC in hippocampal slices (Figure A1 in Appendix), indicating that TRPV4 activation enhances synaptic transmission. Therefore, the enhancement of NMDAR response or/and increase in glutamate release is likely involved in TRPV4-mediated neuronal injury during stroke.

TRPV4 forms calcium-permeable, non-selective cation channels (Plant and Strotmann, 2007). Many studies including ours have reported that activation of TRPV4R causes an increase in intracellular calcium (Liu et al., 2007; Plant and Strotmann, 2007). Reactive oxygen species (ROS) and nitric oxide (NO) are important pathophysiological mediators of ischemia-induced toxicity (Loh et al., 2006). Recent studies performed in the urothelial cells, human coronary arterial endothelial cells, and lung macrophages have reported that activation of TRPV4 can stimulate the production of \( \text{H}_{2}\text{O}_2 \) and NO, which is mediated by TRPV4-induced increase in intracellular calcium (Donkó et al., 2010; Li et al., 2011a; Bubolz et al., 2012). Therefore, it is possible that during stroke, TRPV4 over-activation exacerbates ROS and NO production to induce neuronal injury.

It has recently been reported that TRPV4 and aquaporin-4 (AQP4) are co-expressed in astrocytic plasma membranes in situ, as well as in primary cultures and transfected cell lines (Benfenati et al., 2011). AQP4 plays an important role in keeping water balance in BBB and is involved in the formation of vasogenic brain edema (Zador et al., 2009). AQP4 and TRPV4 form a complex in the astrocytes that is essential for the brain's volume homeostasis by acting as an osmosensor (Benfenati et al., 2011). Moreover, TRPV4 may participate in the pathogenic mechanisms of astroglial reactivity following ischemic insult because it is involved in ischemia-induced calcium entry in reactive astrocytes (Butenko et al., 2012). TRPV4 antagonists increase the viability of astrocytes in oxidative stress-induced cell damage (Bai and Lipski, 2010). The experiment performed on primary cultures of human respiratory epithelial cells shows that TRPV4 mediates calcium influx into human bronchial epithelia upon exposure to diesel exhaust particle, which leads to the activation of matrix metalloproteinase-1 (MMP-1; Li et al., 2011a). MMP-2 and MMP-9 are able to digest the endothelial basal lamina, resulting in opening of BBB. After cerebral ischemia, levels of MMP-2 and MMP-9 are increased, which plays an active role in the formation of brain edema and the secondary brain injury. More experiments will be needed to reveal a possible involvement of TRPV4 activation and MMPs activation in ischemia brain. Therefore, TRPV4 over-activation may also be responsible for the formation of vasogenic brain edema through facilitating AQP4 function or exacerbating the injury of astrocytes or/and basement membrane to increase the permeability of BBB.

In conclusion, this study shows that activation of TRPV4 potentiates NMDAR response, which may facilitate and prolong the glutamate excitotoxicity. Therefore, closing TRPV4 may effectively inhibit \( [\text{Ca}^{2+}]_i \), overload and avoid the side effects through not directly inhibiting NMDAR. Ischemic injury is a complex insult, and treatment with a cocktail for multi-target is a more effective therapeutic strategy. The neuroprotection of TRPV4 antagonist exhibits long time-window (at least 12 h), which also indicates that the neuroprotective effect of closing TRPV4 may be mediated through multiple mechanisms. The present study suggests that TRPV4 is a promising novel target for treatment of ischemic stroke.
ACKNOWLEDGMENTS

This work was supported by National Natural Science Foundation of China (31271206 and 30900577), Science and Technology Project of Jiangsu Province (BK2009416 and BK2011029), Basic Medical Advantage Disciplines Project of Nanjing Medical University (JX10131801055), and Graduate Students Scientific Research Innovation Project of Jiangsu Province (CXXZ12_0567).

REFERENCES

Bai, J. Z., and Lipski, J. (2010). Differential expression of TRPM2 and TRPV4 channels and their potential role in oxidative stress-induced cell death in organotypic hippocampal cultures. Neurotoxicology 31, 204–214.

Benfenati, V., Caprini, M., Dovizio, M., Mylonakou, M. N., Ferroni, S., Ottersen, O. P., et al. (2011). An aquaporin-4/transient receptor potential vaniloid 4 (AQP4/TRPV4) complex is essential for cell volume control in astrocytes. Proc. Natl. Acad. Sci. U.S.A. 108, 2563–2568.

Bubolz, A. H., Mendoza, S. A., Zheng, X., Zinkevich, N. S., Li, R., Gutterman, D. D., et al. (2012). Activation of endothelial TRPV4 channels mediates flow-induced dilation in human coronary arteries: role of Ca2+ entry and mitochondrial ROS signaling. Am. J. Physiol. Heart Circ. Physiol. 302, H634–H642.

Butenko, O., Dzamba, D., Benesova, J., Honsa, P., Benfenati, V., Rusnakova, V., et al. (2012). The increased activity of TRPV4 channel in the astrocytes of the adult rat hippocampus after cerebral hypoxia/ischemia. PLoS ONE 7, e39959. doi:10.1371/journal.pone.0039959

Chen, L., Liu, C., and Liu, L. (2008a). Changes in osmolality modulate voltage-gated calcium channels in trigeminal ganglion neurons. Brain Res. 1208, 56–66.

Chen, L., Liu, C., and Liu, L. (2008b). The modulation of voltage-gated potassium channels by an isotonicity in trigeminal ganglion neurons. Neuroscience 154, 492–495.

Chen, L., Liu, C., Liu, L., and Cao, X. (2009). Changes in osmolality modulate voltage-gated sodium channels in trigeminal ganglion neurons. Neurosci. Res. 64, 199–207.

Donko, A., Ruisanchez, E., Orient, A., Entydi, B., Kapui, R., Petfer, Z., et al. (2010). Urothelial cells produce hydrogen peroxide through the activation of Duox1. Free Radic. Biol. Med. 49, 2040–2048.

Everaerts, W., Zhen, X., Ghosh, D., Vries, J., Gevaert, T., Gilbert, J. P., et al. (2010). Inhibition of the cation channel TRPV4 improves bladder function in mice and rats with cyclophosphamide-induced cystitis. Proc. Natl. Acad. Sci. U.S.A. 107, 19015–19019.

Garcia-Elias, A., Lorenzo, J. M., Vicente, R., and Valverde, M. A. (2008). IP3 receptor binds to and sensitizes TRPV4 channel to osmotic stimuli via a calmodulin-binding site. J. Biol. Chem. 283, 31284–31288.

Kauer, J. A., and Gibson, H. E. (2009). Hot flash: TRPV channels in the brain. Trends Neurosci. 32, 215–224.

Kemp, J. A., and McKernan, R. M. (2002). NMDA receptor pathways as drug targets. Nat. Neurosci. 5, 1039–1042.

Laurie, D. J., Bartle, I., Schoepfer, R., Naujoks, K., and Seeburg, P. H. (1997). Regional, developmental and interspecies expression of the four NMDAR2 subunits, examined using monoclonal antibodies. Brain Res. Mol. Brain Res. 51, 23–32.

Li, J., Kanju, P., Patterson, M., Chew, W. L., Cho, S. H., Gilmour, I., et al. (2008). CASK Functions as a Mg2+-independent neurexin kinase. Cell 133, 328–339.

Mukherjee, K., Sharma, M., URLaub, H., Bourenkov, G. P., Jahn, R., Sudhof, T. C., et al. (2008). CASK Functions as a Mg2+-independent neurexin kinase. Cell 133, 328–339.

Mulcahy, N. L., Ross, J., Rothwell, N. J., and Lodderick, S. A. (2003). Delayed activation of interleukin-1 receptor antagonist protects against transient cerebral ischemia in the rat. Br. J. Pharmacol. 140, 471–476.

Paschen, W. (1996). Glutamate excitotoxicity in transient global cerebral ischemia. Acta Neurobiol. Exp. (Wars) 56, 313–322.

Plant, T. D., and Strotmann, R. (2007). TRPV4. Handb. Exp. Pharmacol. 179, 189–205.

Schmidt-Kastner, R., and Freund, T. F. (1991). Selective vulnerability of the hippocampus in brain ischemia. Neuroscience 40, 599–636.

Shibasaki, K., Suzuki, M., Mizuno, A., and Tominaga, M. (2007). Effects of body temperature on neural activity in the hippocampus: regulation of resting membrane potentials by transient receptor potential vanilloid 4. J. Neurosci. 27, 1566–1575.

Simard, J. M., Kent, T. A., Chen, M., Tarasov, K. V., and Gerzanich, V. (2007). Brain oedema in focal ischaemia: molecular pathophysiology and theoretical implications. Lancet Neurol. 6, 258–268.

Szydlowska, K., and Tymianski, M. (2010). Calcium, ischemia and excitotoxicity. Cell Calcium 47, 122–129.

Zador, Z., Stiver, S., Wang, Y., and Manley, G. T. (2009). Role of aquaporin-4 in cerebral edema and stroke. Handb. Exp. Pharmacol. 190, 159–170.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 30 October 2012; accepted: 09 February 2013; published online: 04 March 2013.

Citation: Li L, Qu W, Zhou L, Lu Z, Jie Chen and Chen L. (2013). Activation of transient receptor potential vanilloid 4 increases NMDA-mediated current in hippocampal pyramidal neurons. Front. Cell. Neurosci. 7:17. doi: 10.3389/fncel.2013.00017

Copyright © 2013 Li, Qu, Zhou, Lu, Jie, Chen and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc.
APPENDIX

300mOsm/kg  4α-PDD  washout

50pA  50ms

FIGURE A1 | Effect of 4α-PDD on EPSC in hippocampal slices. EPSCs recorded from CA1 pyramidal neurons of hippocampal slices before, during, and after 4α-PDD (10 µM) application. On the average, EPSC slope was enhanced 42.1 ± 5.0% by 4α-PDD (n = 8, paired t-test, P < 0.01). EPSC was evoked by stimulating Schaffer fibers through a constant-current pulse delivered by a Master-8 Stimulator (AMPI, Jerusalem, Israel). Hippocampal CA1 neurons were held at -70 mV and perfused with oxygenated bath solution composed of (in mM) NaCl 126, CaCl2 1, KCl 2.5, MgCl2 1, NaHCO3 26, KH2PO4 1.25, d-glucose 20, bicuculline 0.01, and TTX 0.1 µM. Pipette solution was composed of (in mM) Cs-gluconate 132.5, CsCl 17.5, MgCl2 2, EGTA 0.5, HEPES 10, ATP 4, and QX-314 [N-(2,6-Dimethylphenylcarbamoylmethyl) triethylammonium bromide] 5 and pH was adjusted to 7.2 by CsOH.